BioSpace

Cellectis could cut 70% of workforce in shift to in vivo therapies

Cellectis’ business transformation could cost around 160 global employees their jobs. The company has stopped enrollment in its two CAR T programs as it focuses on trials of its in vivo candidates.

By BioSpace

1 min read
Cellectis could cut 70% of workforce in shift to in vivo therapies
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights